What Is The Ownership Structure For Inovio Pharmaceuticals, Inc. (INO)?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) with the stream of -1.10% in the last hour of trading session. If you want to know who really controls Inovio Pharmaceuticals, Inc. (NASDAQ:INO), then you’ll have to look at the makeup of its share registry. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that have been privatized tend to have low insider ownership.

Inovio Pharmaceuticals isn’t enormous, but it’s not particularly small either. It has a market capitalization of US$1.9b, which means it would generally expect to see some institutions on the share registry. In the chart below, we can see that institutions are noticeable on the share registry. We can zoom in on the different ownership groups, to learn more about Inovio Pharmaceuticals.

What Does The Institutional Ownership Tell Us About Inovio Pharmaceuticals?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

Inovio Pharmaceuticals already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It’s therefore worth looking at Inovio Pharmaceuticals’ earnings history below. Of course, the future is what really matters.

We note that hedge funds don’t have a meaningful investment in Inovio Pharmaceuticals. Our data shows that BlackRock, Inc. is the largest shareholder with 8.1% of shares outstanding. With 5.5% and 4.7% of the shares outstanding respectively, The Vanguard Group, Inc. and State Street Global Advisors, Inc. are the second and third largest shareholders. In addition, we found that J. Kim, the CEO has 1.2% of the shares allocated to their name.

On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock’s expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Inovio Pharmaceuticals

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

We can see that insiders own shares in Inovio Pharmaceuticals, Inc.. This is a big company, so it is good to see this level of alignment. Insiders own US$30m worth of shares (at current prices). It is good to see this level of investment by insiders.

General Public Ownership

The general public, who are mostly retail investors, collectively hold 51% of Inovio Pharmaceuticals shares. This size of ownership gives retail investors collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.

Inovio Pharmaceuticals, Inc. (INO) shares fell -1.10% to close at $9.00. About 13,416,452 million shares traded hands on 10.98M trades for the day, compared with an average daily volume of 10.98M shares out of a total float of 166.05M. After opening the trading day at $9.00, shares of Inovio Pharmaceuticals, Inc. stayed within a range of $8.81 to $9.30.

With today’s loss, Inovio Pharmaceuticals, Inc. now has a market cap of $1.48B. Shares of Inovio Pharmaceuticals, Inc. have been trading within a range of $3.14 and $33.79 over the last year, and it had a 50-day SMA of $-14.37% and a 200-day SMA of $-34.69%.

The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E ratio. Last traded has a PEG ratio of 0 where as its P/E ratio was 0. The overall volume in the last trading session was 13,416,452 shares.

Important Results:

Inovio Pharmaceuticals, Inc. has P/S value of 704.27 while its P/B esteem remains at 4.59. Likewise, the company has Return on Assets of -52.70%, Return on Equity of -103.00% and Return on Investment of -137.90%. The company demonstrates Gross Margin and Operating Margin of 0 and 0 respectively.

INO’s price to sales ratio for trailing twelve months was 704.27 and price to book ratio for most recent quarter was 4.59, whereas price to cash per share for the most recent quarter was 4.39. The Company’s price to free cash flow for trailing twelve months was recorded as 0.

Historical Performances to Consider:

The Stock’s performances for Monthly, weekly, half-yearly, quarterly & year-to-date are mentioned below:-

On a Monthly basis the stock was -12.88%. On a weekly basis, the stock remained -3.95%. The half-yearly performance for the stock has -63.38%, while the quarterly performance was -14.29%. Looking further out we can see that the stock has moved 1.69% over the year to date. Other technical indicators are worth considering in assessing the prospects for EQT. RSI for instance was stand at 40.88.

Jake Charles

About Jake Charles

This is Jake Charles, a Senior News Writer for “Stocks Equity”. I covers “Active Stocks” sector and writes about trending Active Hot companies from an exclusive and “out of the box” perspective. I worked independently as a self motivator and with the financial institute as financial adviser to invest in the Active sector for over 9 years in the developing countries by introducing new phases and ways to improve in this sector. I like to travel all over the globe to get new experience and provide by best services to the companies. As an advisor I like to work with new people to share and explore new ideas keeping in view minimizing the operating cost and giving the best final product through new technology and minimizing the time of development.

View all posts by Jake Charles →

Leave a Reply

Your email address will not be published. Required fields are marked *